Edwards Lifesciences (EW) Total Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences has reported Total Non-Current Liabilities for 18 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 4.45% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 4.45% increase from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 9.55% from the prior year.
• Total Non-Current Liabilities was $2.6 billion for Q2 2026 at Edwards Lifesciences, up from $2.4 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $3.0 billion in Q3 2024, with the low at $2.1 billion in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $2.4 billion, with a median of $2.3 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities climbed 29.28% in 2024, then retreated 12.94% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $2.2 billion in 2022, then advanced by 4.08% to $2.3 billion in 2023, then rose by 12.95% to $2.6 billion in 2024, then rose by 9.55% to $2.9 billion in 2025, then dropped by 10.04% to $2.6 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.6 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.9 billion (Q4 2025), per Business Quant data.